Both BRD7 and BRD9 have been identified as members of the SWI/SNF nucleosome remodeling complex,68,69 which has emerged as an attractive target for developing anti-cancer agents.70 BRD7 is frequently found as a tumour suppressor,71–73 whereas BRD9 has been found to be mutated,74 upregulated,75 or over-expressed76 in various cancers. Here, SMARCA1 is linked to cancer.